NASDAQ : CLOV

Clover Health Investments, Corp.

$4.6713 USD

-$0.01 (-0.19%)

Volume
442.64K
Average Volume
7.84M
Market Capitalization
$2.42B
P/E Ratio
-41.97
Dividend Yield
0.00%
Price Target
$4.48
Year High
$5.59
Year Low
$1.58
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.33
Source Headline
Clover Health to Report Second Quarter 2026 Financial Results on August 5, 2026

WILMINGTON, Del., July 09, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026.

globenewswire.com - 2026-07-09 16:05:00

Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up

SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover” or “Clover Health”), and a leading AI-powered physician enablement platform, today released findings within the whitepaper  “Clinical Excellence in Continuity of Care: A Real-World Analysis of Counterpart Assistant's Role in Post-Hospitalization Follow-up.” The whitepaper examines the relationship between CA use by primary care physicians (“PCPs”) and performance on high-risk care transition outcomes, including two HEDIS®1 quality measures within Clover Health's Medicare Advantage population: Transitions of Care (“TRC”) and Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (“FMC”).

globenewswire.com - 2026-07-07 08:30:00

Clover Health's CEO Sold Company Shares Worth $1.7 Million. Here's What That Means for Investors.

CEO Andrew Toy sold 313,476 shares of Common Stock for a transaction value of ~$1.67 million as of July 1, 2026. This transaction represented 3.16% of Toy's direct holdings, reducing direct ownership to 9,609,825 shares.

fool.com - 2026-07-06 20:32:01

A Clover Health Director Sold Over 67,000 Company Shares. Here's a Closer Look at the Transaction.

Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.

fool.com - 2026-06-27 13:13:01

Clover Health Stock Extends Gains After Court Forces CMS to Upgrade Medicare Star Rating

Clover Health Investments Corp. (NASDAQ:CLOV) shares are extending yesterday's 18.9% surge Thursday, after a court-ordered Medicare Star Rating upgrade jumped its PPO plan from 3.5 to 4.5 Stars.

benzinga.com - 2026-06-11 07:32:42

A Clover Health Insider Sold Over 220,000 Company Shares. What Does That Mean for Investors?

This healthcare technology company focused on Medicare Advantage plans saw a notable insider sale following a year of strong stock gains.

fool.com - 2026-06-05 14:04:01

Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 13:11:16

Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises

CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.

zacks.com - 2026-05-07 12:51:01

Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.

zacks.com - 2026-05-06 19:35:40

Clover Health Reports First Quarter 2026 Results

Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with expectations Expect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year First quarter 2026 Consolidated Gross Profit of $160 million, up 47% year-over-year, and Adjusted EBITDA of $40 million, up 56% year-over-year Full Year 2026 Guidance: Average Medicare Advantage membership of 154,000 - 158,000, representing 46% growth year-over-year at the midpoint Total revenues between $2.81 billion and $2.92 billion, representing 49% growth year-over-year at the midpoint Consolidated Gross Profit between $470 million and $510 million, representing 38% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million GAAP Net Income between $0 million and $20 million WILMINGTON, Del., May 06, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2026.

globenewswire.com - 2026-05-06 16:05:00

Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.

zacks.com - 2026-04-30 08:41:13

Get CLOV Insider Trade Alerts

CLOV Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$4.47

2 analysts

Last Year

$3.98

3 analysts

All Time

$3.71

6 analysts

CLOV Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-06-11 UBS Maintain Neutral Neutral
2026-06-04 Canaccord Genuity Maintain Buy Buy
2026-03-20 Canaccord Genuity Maintain Buy Buy
2026-03-05 Leerink Partners Maintain Market Perform Market Perform
2026-01-20 Canaccord Genuity Maintain Buy Buy
2025-11-06 Canaccord Genuity Maintain Buy Buy
2025-08-07 Canaccord Genuity Maintain Buy Buy
2025-08-06 UBS Maintain Neutral Neutral
2025-03-03 Canaccord Genuity Maintain Buy Buy
2023-08-11 Citigroup Maintain Neutral Neutral
2023-03-06 Canaccord Genuity Maintain Buy Buy
2023-03-06 Credit Suisse Maintain Underperform Underperform
2022-11-16 Citigroup Maintain Neutral Neutral
2022-11-08 SVB Leerink Maintain Market Perform Market Perform
2022-08-09 Citigroup Maintain Neutral Neutral
2022-08-09 Credit Suisse Maintain Underperform Underperform
2022-05-10 SVB Leerink Maintain Market Perform Market Perform
2022-02-25 SVB Leerink Maintain Market Perform Market Perform
2022-02-02 Cowen & Co. Upgrade Underperform Market Perform
2022-01-07 Credit Suisse Downgrade Neutral Underperform
2021-11-15 Credit Suisse Maintain Neutral Neutral
2021-07-12 JP Morgan Downgrade Neutral Underweight
2021-06-10 B of A Securities Downgrade Neutral Underperform
2021-05-19 Credit Suisse Maintain Neutral Neutral
2021-05-17 B of A Securities Downgrade Buy Neutral